Web
Analytics
The news is by your side.

impair

Cholesterol-slashing drug does not impair brain: study

WASHINGTON: A new cholesterol-slashing drug that has shown promise for high-risk patients does not impair brain function, according to a study out Saturday. Previous research had raised the possibility that evolocumab, sold under the brand name Repatha by Amgen, may have a damaging effect on memory and cognitive function. Evolocumab is part of a new class of cholesterol-lowering drugs called PCSK9 inhibitors, which dramatically lower bad cholesterol, or low-density lipoprotein (LDL). The drug has been shown to…